fashion -WSS

fashion

author：leisure time 2025-10-02 23:31:07 - browse：4

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Patients, digital health players weigh in on FTC's data privacy plan

leisure time

explore

WSS

BMS, looking to build heart drug business, turns to AI for diagnosis

Aspartame and sugar

Hospitals are dialing back on venture capital investing

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

When women are denied an abortion, their children fare worse than peers

Surge in Apellis stock fueled by confidence in safety of its eye drug

focus

fashion

focus

As demand for Covid shots wanes, Moderna seeks its next success

Treatments for cramps don't cut it. Why aren't there better options?

Activists slam private health insurers over coverage restrictions

Timeline: How the deadly wildfires took over Maui day by day

Peter Hotez and the public health issue of online harassment

Illumina slashes 2023 revenue projections yet again

At least 13 dead in Texas as scorching temps continue

Novo Nordisk touts Wegovy study, but still struggling with supply

Virginia high school admissions case could be legal follow

Bristol 'take

focus

FDA panel signals lack of confidence in Amgen cancer drug data

YouTube cracks down on misinformation on cancer treatment

Stroke deaths set to near 10 million globally by 2050

Senate panel eyes new effort on drug shortages

When women are denied an abortion, their children fare worse than peers

Schizophrenia gene found to be linked to cells' energy dysfunction

leisure time

explore

knowledge

entertainment